Podcasts about syneos health

Hosted by Drew Beck, Head of Strategy, Growth and Innovation for Syneos Health Learning Solutions, this limited series dives into the breakthrough trends redefining health in 2025 and beyond. From bold moves in R&D and medical affairs to next-gen trial design, product launch strategies and the future of healthcare communications, each episode connects you with the minds driving real change. Big ideas. Real-world impact. In this episode, Drew dives into launch excellence in 2025 with Syneos Health experts Larry Dollar, VP of Medical Affairs, and Michael Sarshad, Managing Director, Consulting. Together, they unpack how strategic spending, agile planning and early investment in medical resources are driving launch success. They explore the rise of new medical affairs roles using the transformative impact of AI on clinical trials, and the evolving needs of field teams. The discussion also highlights how innovations like machine learning–driven physician segmentation are helping companies identify new clinical trial sites faster and more precisely. Whether you're with an emerging biotech or a large pharma company, you'll get key insights on collaboration, creativity and why the year leading up to launch is more critical than ever. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

2025 Health Trends meets The Syneos Health Podcast for a limited series exploring how Trends come alive in the life sciences industry with host Drew Beck, Head of Strategy, Growth and Innovation for Syneos Health Learning Solutions. Syneos Health experts Brian Carver, Executive Director of Therapeutic Strategy and Innovation, Rare Disease Consortium, Vik Chawla, Managing Director, Syneos Health Consulting and Katya Magonova, Managing Director, Syneos Health Consulting explore the role of AI in rare disease drug development, diagnosis and treatment. They share how AI is accelerating R&D, improving patient identification and enhancing clinical trials. The discussion also highlights investment trends in AI within the healthcare sector, the emergence of AI-first companies and the ongoing challenges and opportunities of integrating AI into life sciences, underpinned with data from our 2025 Dealmakers' Intentions Survey. Emphasizing the importance of understanding AI's applications and implications, host Drew Beck has a special call to action for the industry to harness AI's power in drug development and commercialization today. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

The biopharma market is booming—but not without turbulence. In this kickoff episode of our special podcast series in collaboration with Asembia, hosts Michael Sarshad, Managing Director, Commercial Advisory, Syneos Health and Sara Rubin, Senior Vice President, Market Access Strategy at Spherico, a Syneos Health company, unpack the dynamic forces reshaping how therapies reach patients. Recorded ahead of Asembia's AXS25 Specialty Pharmacy Summit, they dive into the impact of tariffs, the power of AI in streamlining patient support, the ripple effects of the Inflation Reduction Act and how digital transformation is changing the way manufacturers engage population health decision-makers. Tune in for expert insights, preview topics for this year's summit, and discover how the industry is responding to rising complexity with strategic innovation.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Send us a textIn this episode of the Life Science Success Podcast my guest is Matt Veatch, President & COO and Co-Founder of Navidence, Inc., a SaaS company advancing the use of Computable Operational Definitions for real-world data in clinical trials and evidence generation. With over 30 years of experience in biopharmaceutical and medical device development, Matt brings extensive leadership expertise from roles at Syneos Health, Quintiles, and his own consulting practice.00:00 Introduction to Life Science Success Podcast00:30 Meet Matt Veatch: President and COO of Navidence01:22 Matt's Journey in the Life Science Industry05:49 Entrepreneurial Ventures and Consulting06:54 The Birth of Navidence17:26 Navidence's Mission and Impact27:25 Innovative Projects and Partnerships30:58 Matt's Podcast and Personal Insights35:13 Leadership Advice and Inspirations38:55 Concerns and Future Excitements46:33 Conclusion and Farewell

Shauna Keough, President of U.S. Public Relations at Syneos Health, shares how she applies behavioral science to build stronger client relationships. She emphasizes the importance of understanding key factors like risk and work-life balance to gain deeper insights into client mindsets. Shauna also explains how she leverages these insights to strengthen her partnerships and drive success. Learn more about D S Simon Media.

As regulatory expectations evolve under the FDA's Project Optimus oncology dosing initiative, biostatistics is emerging as a central pillar in designing and executing trials that move beyond the traditional maximum tolerated dose (MTD) approach.In this fourth episode of our Project Optimus series, host Dr. Wael Harb is joined by biostatistics expert X.Q Xue, PhD, Vice President and Global Head, Biostatistics at Syneos Health to explore how statistical science is transforming dose optimization in oncology drug development. Dr. Xue discusses the limitations of legacy 3+3 dose-escalation designs and introduces innovative alternatives, including Bayesian modeling, adaptive trial strategies and randomized parallel dose-response studies, which support more precise dose selection and can ultimately improve patient outcomes and trial efficiency.Together, Drs. Harb and Xue examine how smaller biotech companies can overcome barriers to implementation, the role of simulation and AI in trial planning and how a biostatistics-driven approach may increase the likelihood of late-phase success, reduce post-marketing adjustments and support faster regulatory approvals.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Guided by complex regulatory and trademark requirements, brand teams have often had to sacrifice creativity for compliance. Traditional naming methods, unchanged for decades, alongside crowded markets have led to shrinking white space, high attrition rates and weakened brand strategies. In this episode, Joe Daley, president of Addison Whitney, powered by Syneos Health, explores how Ari, the industry's first AI-driven naming platform, is breaking through these barriers. By integrating real-time regulatory and trademark screening, Ari expands creative white space within set guardrails, empowering deeper strategic exploration and compliance like never before possible — reducing risk while increasing creativity. Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

In this episode of The Syneos Health Podcast, we continue our exploration of Project Optimus and the evolution of dose optimization in oncology drug development. Following our discussion on regulatory expectations in the previous episode, we now turn to the operational challenges and strategies required to implement optimized dosing in real-world settings.Host Dr. Wael Harb is joined by Patrick Melvin, Vice President, Oncology & Hematology and Global Head, Novel and Emerging Therapies at Syneos Health, to discuss the complexities of operationalizing Project Optimus. Together, they examine how drug developers, investigator sites and patients are affected by these changes, the role of adaptive study designs, and how AI-driven technologies and digital health innovations are helping to streamline dose optimization.Tune in to gain valuable insights into the future of precision dosing and the long-term benefits of this industry shift, from improving patient outcomes to enhancing drug development efficiency.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Ever had a work dilemma so awkward you'd rather fake a panic attack than ask your boss? Well, we've got you covered. This week, our expert agony aunts tackle your toughest questions, including:

What separates top-performing medical sales reps from the rest?  It's not just talent; it's elite training. Amy Harrington, VP of Clinical Training, reveals how the right approach to learning can make or break your success in this industry. Inside this episode: How Amy went from surgical tech to nurse to top-tier medical sales leader Why sales training isn't optional—it's the secret weapon for dominating the field The overlooked power of personalized learning in high-stakes industries How startups shaped her ability to adapt, innovate, and build winning teams Whether you aim to break in, level up, or reinvent your career, this episode delivers the insider playbook for thriving in medical sales. Meet the guest:  Amy Harrington is the Vice President of Clinical Training and Practice Development at R2 Technologies, Inc., where she leads the company's clinical education and advancement strategies. With over a decade of experience in the aesthetic and medical technology industries, Amy is known for designing innovative training programs that equip sales teams to sell confidently through science and knowledge. Since joining R2 in 2021, Amy has been a driving force behind the company'scompany's growth and innovation. Her strategic leadership—first as Director of Clinical Development & Education, then as Senior Director of Clinical Development, and now as VP of Practice Development—has been instrumental in establishing the R2 brand within clinical practices. Her contributions reflect a deep commitment to advancing the field of aesthetics through education and collaboration. Before R2, Amy held impactful leadership roles at Syneos Health, Obagi, and Solta Medical, where she developed and implemented transformative clinical and sales training programs. Beginning her career as a Registered Nurse in the operating room, she gained invaluable hands-on experience that continues to inform her practical and patient-centered approach to clinical education. Amy's academic background includes a dual bachelor's Degree in nursing and biology from the University of Maine, as well as an associate's Degree in criminalistics. She further enhanced her expertise in curriculum development with an instructional design certification from the Association of Talent Development. Outside of her professional endeavors, Amy is a wellness enthusiast who enjoys yoga, rowing, and exploring Maine's landscapes. A proud dog mom, she embraces an active outdoor lifestyle while balancing her passion for transforming clinical education with her love for the outdoors.  Connect with her:  LinkedIn Instagram

In this episode, we welcome Dr. Rishi Kakar, Chief Scientific Officer and Medical Director at Segal Trials. Host Andy Moniz, Vice President, Therapeutic Strategy & Innovation at Syneos Health, sits down with Dr. Kakar to explore his inspiring journey from a 15-year-old immigrant discovering neuroscience in a Queens library to becoming a leader in clinical research and innovation.Dr. Kakar shares the personal moments that shaped his passion for psychiatry, the pivotal experiences that drove his commitment to understanding the drug development process, and how Segal Trials has remained at the forefront of clinical research. From pioneering psychedelic trials to building innovative quality dashboards, Dr. Kakar offers insights into the future of patient-centric clinical trials, workforce transformation, and the integration of emerging technologies.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In this episode of the Syneos Health Podcast, series host Dr. Wael Harb, Vice President of Medical Management at Syneos Health, continues the exploration of FDA's groundbreaking Project Optimus and its profound implications for oncology drug development. He is joined by Zohra Lomri, Executive Director, Regulatory Affairs at Syneos Health, to discuss how this initiative is transforming dose optimization strategies and reshaping the clinical trial landscape.The conversation delves into the FDA's emphasis on balancing efficacy and tolerability, the shift away from maximum tolerated doses, and the integration of patient-reported outcomes. Zohra provides valuable insights on the regulatory expectations for dose-ranging studies, the importance of leveraging non-clinical data, and the role of pharmacokinetics (PK) and pharmacodynamics (PD) modeling in optimizing trial designs.Whether you're in oncology drug development or interested in regulatory innovation, this episode offers actionable advice and a glimpse into the future of patient-focused drug development.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Georgie Kovacs is a seasoned professional with over two decades of healthcare expertise, having contributed to industry giants like Pfizer, Syneos Health, IQVIA, and Bristol-Myers Squibb. She launched Fempower Health in 2020, a pioneering platform that empowers women with evidence-based insights and support. Collaborating with top experts, Georgie is dedicated to redefining the narrative surrounding women's health, ensuring every woman has the knowledge and resources to thrive and make informed decisions about their health. In this episode, Georgie opens up about her personal and professional story, shaped by her roots as the daughter of Hungarian immigrants and the challenges of forging her path in the healthcare industry. Discover her unique approach to overcoming obstacles, her mental strength cultivated through long-distance running, and the lessons she's learned about breaking down big problems into manageable steps. Tune in for a conversation filled with vulnerability, grit, and actionable insights that will leave you inspired to tackle your own challenges head-on. Don't miss Georgie's powerful message about persistence, self-discovery, and creating a meaningful impact in the world. Website- https://www.fempower-health.com/ Social Media Links/Handles- https://www.instagram.com/fempowerhealth https://www.youtube.com/@fempowerhealth

Recorded from the 15th annual CNS Summit, Andy Moniz, Vice President of Therapeutic Strategy Innovation at Syneos Health, sits down with Jane Metcalfe, Board Chair of the Human Immunome Project, to discuss the transformative potential of immunology in medicine. Jane shares her inspiring journey into this groundbreaking field, highlighting how advanced biological measurements, machine learning, and personalized immune profiling are reshaping drug development, clinical practice, and medical education.From the immune system's role in diseases like Alzheimer's and cancer to the need for diverse clinical trials, this conversation explores the dynamic intersection of science, technology, and humanity.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Join host Andy Moniz, Vice President of Therapeutic Strategy Innovation at Syneos Health, as he sits down with Dr. David Brown from Community Clinical Research in Austin, Texas, for a compelling conversation recorded from the floor of CNS Summit. In this episode, Dr. Brown shares his journey into psychiatry, inspired by his experiences in medical school and his personal connection to mental health.The discussion delves into the transformative impact of clinical trials, the advancements in schizophrenia research, and the potential for a new era in personalized psychiatry driven by genetic insights and AI. Dr. Brown reflects on the challenges of stigma, the progress in neuroscience, and his hopes for the industry in the next five years, including bridging gaps between academia and pharma and inspiring the next generation of researchers.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In this episode, recorded from the floor of the CNS Summit, host Andy Moniz, Vice President of Therapeutic Strategy and Innovation at Syneos Health, sits down with Cristina Duran, CEO of Evinova, to discuss her transformative journey in life sciences and the future of patient-centric innovation in healthcare.Cristina shares insights from her experience leading R&D transformation at AstraZeneca, where she pioneered patient-centric approaches to clinical trials. She discusses how Evinova is driving industry-wide change by creating integrated, scalable solutions that prioritize patient needs while delivering faster, more efficient outcomes for life sciences—emphasizing the importance of collaboration, learning from failures, and connecting across the sector to accelerate progress.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In this special series of the Syneos Health Podcast, we celebrate 15 years of innovation in collaboration with CNS Summit, a community of innovators and life science industry leaders devoted to discovering better, more efficient ways to advance the industry through innovation, collaboration, and technology. Over the course of the series, we will feature conversations with key experts and members of the community on how the life sciences industry is continuing to reinvent itself in the pursuit of better outcomes for more patients.In this episode, guest host Dr. Alexandria Wise, SVP and Global Neuroscience Head at Syneos Health, is joined by physician-scientist Dr. Amir Kalali, Chairman and Chief Curator of CNS Summit. Dr. Kalali shares the origins of CNS Summit, the unique vision that set it apart, and the milestones achieved along the way—and offers insights on the future of collaboration in clinical development and advice for the next generation of industry leaders.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Launched in 2021 by the FDA's Oncology Center of Excellence, Project Optimus seeks to reshape traditional oncology trial designs and dosing paradigms, shifting from maximum tolerated doses to precision dosing strategies. While the FDA's hope was that the added time and cost of collecting comprehensive dose and exposure response data would benefit both patients and sponsors, there is also concern and debate in the biotech community that, if the Optimus formula is closely followed, the additional time, cost, and patient needs may, in fact, be crippling to cash-strapped emerging companies. So what is the reality around Project Optimus? And how best can it be implemented and navigated?Kicking off a new special series on Project Optimus, in this episode Nick Kenny, Chief Scientific Officer at Syneos Health, is joined by Dr. Wael Harb, Vice President on the Syneos Health Medical Oncology Team, to explore this transformative initiative, diving into the implications for biotech companies and discussing the balance between upfront investment and long-term benefits, the operational challenges of implementation, and the critical role of early planning.Stay tuned for upcoming episodes in this series, which will dive deeper into the regulatory, statistical, clinical, and operational implications of this evolving regulatory framework.For more insights from our oncology experts:Syneos Health Podcast | A Site-Specific Approach to Optimizing Diversity in Oncology TrialsWEBINAR | Transforming Oncology Drug Development: Insights from Healthcare Providers on the Frontlines of Cancer CareSyneos Health Podcast | Circulating Tumor DNA: Transforming Oncology Clinical TrialsNavigating Tumor-Agnostic Drug Development: Value, Challenges and Strategic Insights for SponsorsThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

2024-11-22 Hosts Craig Lipset, Amir Kalali, and Jane Myles were joined by Keith Robinson, MD, MS, FCCP and Megan Parisi, MS, CCRP from Syneos Health and Nick Delmonico from Strados Labs for a discussion around wearables. We discussed challenges in increasing adoption of wearables, factors that are holding things back from greater widespread adoption, and the benefits/ROI of wearables and novel measurements.You can join TGIF-DTRA Sessions live on LinkedIn Live Audio on Friday's at 12:00 PM ET by checking out our LinkedIn. Follow the Decentralized Trials & Research Alliance (DTRA) on LinkedIn and X. Learn more about Membership options and our work at www.dtra.org.

There is a significant unmet need for medicines to treat neuropsychiatric and neurological conditions in underserved patient populations. Recently, there has been renewed interest in psychedelic, hallucinogenic and dissociative compounds to meet those needs. In clinical trials, a wide array of these compounds are showing efficacy across a variety of indications. Syneos Health experts Andy Moniz, Dr. Leslie Moldauer, Zelma Gandy Don Sing and Lindsay Crampton—along with Dr. Aaron Koenig, CMO of Delix Therapeutics—convened in a roundtable discussion to provide their own unique perspectives about the current and future state of psychedelic drug development and how to actively navigate the rapidly evolving field of clinical trials for these revolutionary treatments. Listen in to hear how psychedelics have progressed from their origins as a spiritual aid, their acceptance as a treatment for neuropsychiatric conditions, and the development of next-generation compounds. For more from our neuroscience experts, check out these insights: Syneos Health Podcast | Can AI Help Get the Right Patients Into Alzheimer's Clinical Trials?Artificial Intelligence and Alzheimer's: Transforming Patient Screening with Predictive ModelsWEBINAR | Psychedelics 3.0: Challenges and OpportunitiesSyneos Health Podcast | World Mental Health Day: The State of Mental Health Clinical DevelopmentBLOG | The Reimbursement Case for Psychedelic Therapies Must Incorporate the Patient's VoiceThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

As the biopharma industry strives to ensure that clinical trials reflect the rich diversity of the patient populations they aim to serve, the challenges to make this possible have fallen on the trial sites. In a recent webinar, Syneos Health experts Jane Bentley and Juliette Roberts from our Oncology Therapeutic Strategy & Innovation team, and Kelli Defenbaugh from Patient Recruitment and Retention Management, offered robust strategies and actionable insights tailored to overcome obstacles sites are facing.Listen in to learn more about how sites can contribute to enhanced diversity in oncology trials, with specific actions that sites can take to make each clinical trial better represent the population it seeks to serve.Visit here for more oncology insights from our experts.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Join Oliver Nelson, managing director at Evolvics, powered by Syneos Health; and Matt Snodgrass, AI innovation lead at Syneos Health, live on the floor at Digital Pharma East as they discuss conference insights, industry trends, digital transformation and patient engagement.Check us out at: mmm-online.com   Follow us:  YouTube: @MMM-online TikTok: @MMMnews Instagram: @MMMnewsonline Twitter/X: @MMMnews LinkedIn: MM+M   To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

Jeanine O'Kane is president of Syneos Health Communications — a portfolio of agencies spanning advertising, public relations, patient advocacy, medical communications, managed markets and naming and branding. Formerly president of the US public relations group at Syneos Health Communications, Jeanine has been with the organization for more than a decade and has more than 20 years of industry experience. During her tenure at Syneos Health Communications, she has been instrumental in developing award-winning communications programs and has helped integrate communications and commercial expertise into clinical development, unlocking innovative solutions to deliver life-saving therapies to patients worldwide. Jeanine was named President in April 2023. Since assuming this role, she has been steadfast in her commitment to creating a culture of growth that is rooted in innovation. Read the company's profile here. Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

My guest this week is Michelle Offner, Clinical Nurse Educator at Syneos Health and we discuss the evolving role of Clinical Educators for Pharma and Field Medical This weeks episode is sponsored by Syneos Health Commercial Solutions, the leading provider of the industry's broadest and most fully integrated offerings. Blending a deep understanding of human behavior and the latest technology with hard-earned knowledge and insights gained from supporting the commercialization of more products than any other partner, Syneos delivers predictive solutions that reduce risk, accelerate commercial performance, and fulfill the company's industry promise to patients. For more details, please visit syneoshealth.com   In this episode, we discuss….  Who Clinical Educators call on and who are the main external customers  Who Clinical Educators interact with internally and the main cross functional partners  How Clinical Educators work with commercial counterparts and how does it differ from MSLs  How compliance and regulatory guardrails affect Clinical Educators  and is it the same as the MSL  How Clinical Educators influence health outcomes and what value there  is to patients as well as families   The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel.    MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions.   #msl #medicalaffairs #medicalscienceliaison #msltalk #careers

AI is seemingly everywhere now in our lives, including healthcare and drug discovery and development. AI certainly has the potential to enable major advances than development of more effective and safe medical products. And in fact, GenAI has already been successfully used in drug discovery. But are we fully leveraging the current AI yet in practical ways? Are our trial designs informed appropriately by AI and data? From the mundane document generation and handling to the complex patient engagement, what is the here and now of how we can and should apply AI to support more informed, more effective drug development?In this episode of the Syneos Health Podcast, Nick Kenny, Chief Scientific Officer at Syneos Health is joined by industry experts Nataraj Dasgupta, Vice President of Advanced Analytics at RxDataScience and Greg Christie, Chief Product Officer at StudyKIK to dive deep into the transformative potential of Artificial Intelligence (AI) in the realm of drug development and clinical trials. The discussion explores the practical applications of AI—from improving patient recruitment and engagement to revolutionizing document generation and protocol design—and touches on the exciting promise of Generative AI (GenAI) in streamlining processes, enhancing patient experiences, and democratizing access to clinical trials. The panel also confronts the challenges, including data accuracy, regulatory concerns, and the ethical implications of AI-driven decisions.Tune in to understand how AI is reshaping the future of healthcare and what lies ahead in this rapidly evolving field. For more AI insights from our experts:Syneos Health Podcast | Can AI Help Get the Right Patients Into Alzheimer's Clinical Trials?Artificial Intelligence and Alzheimer's: Transforming Patient Screening with Predictive ModelsSyneos Health Podcast | Turbo-Charging Clinical TrialsWEBINAR | How AI is Supercharging Clinical TrialsThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

The World Economic Forum projects that by 2050, climate change could cause 14 million additional deaths and $12 trillion in global healthcare costs. And this will exacerbate global health inequities with our most vulnerable populations, including women, youth, elderly, lower-income groups, and hard-to-reach communities bearing the brunt of this change. We think we know the culprits…but do we really?The fact is, the healthcare sector is responsible for almost 5% of global greenhouse gas emissions and has a carbon footprint equivalent to 514 coal-fired power plants. And if the healthcare sector was a country, it would be the 5th largest polluter on Earth. (Source)In this episode of the Syneos Health Podcast, Nick Kenny is joined by Syneos Health colleagues Sharon Gordon, leader of our Social Impact practice and Beth Anne McPheeters, head of ESG programming, to discuss the intersection of climate change, ESG (Environmental, Social, and Governance), and healthcare.The conversation delves into the responsibilities of big industries versus collective action, the role of ESG in driving meaningful change, and the importance of integrating ESG into business goals to mitigate risks and create value, ultimately benefiting both business and patient outcomes—reinforcing that addressing climate change and promoting ESG is not just corporate responsibility but also essential for improving global health and equity.For more on how Syneos Health is committed to making purposeful actions upholding our responsibility to create a more sustainable world for each other, read our 2023 ESG Report.Check out more of our insights on the role of ESG in the healthcare industry:BLOG | Pharma Reputation Slipping, Leaving Fewer Allies in Intense EnvironmentBLOG | 4 Reasons ESG Priorities are Becoming More Important in the Life Sciences IndustryClinical Trials and Environmental, Social and Governance: Plans for Operations LeadersThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Today, we're so excited to get to know Web Sun, President and Co-Founder of Komodo Health. Komodo Health leverages data-driven insights to enhance patient care and alleviate disease burdens. Their platform analyzes de-identified real-world data from a wide range of sources to  offer detailed patient-level insights around treatment, diagnosis, costs, and outcomes for millions of patients across the U.S. Web oversees operations including business development, sales and marketing, and people. Prior to founding Komodo Health, Web was a managing director at Zephyr Health, a leading life sciences data and insights solution provider, running all non-Engineering functions. He spent nearly eight years as vice president at Campbell Alliance (now Syneos Health) where he advised enterprise life sciences companies across corporate development, brand management and marketing, commercial effectiveness and medical affairs initiatives. Web also served as an Executive Advisor to Reify Health, Heads Up Health and other healthcare/healthtech startups focused on Big Data, SaaS, Healthcare IT, and Predictive Analytics to improve patient outcomes.  In this episode, we explore Komodo Health's origins, the creation of their MVP and key products, their transformative impact on healthcare, their future with AI, and Web's unique insights for founders navigating the data science and healthcare landscape.

Alzheimer's disease is a challenging and devastating diagnosis that affects memory and cognitive skills, with no known way to predict, track, treat, or cure it effectively. In 2024, around 90 million people over the age of 65 will be living with Alzheimer's. Clinical trials for new treatments have faced high failure rates, partly because it's difficult to identify the right patients at the right stage of the disease. The potential solution to this dilemma might lie in AI, which could help analyze vast amounts of clinical data and provide a practical prognostic tool.Our host Nick Kenny, Chief Scientific Officer at Syneos Health, is joined by Dr. Claudine Brisard, Senior Vice President of Neurosciences at Syneos Health and Dr. Christian Dansereau, CEO of Perceiv AI, to explore how AI and prognostic models might solve the challenges of selecting the right patients for Alzheimer's clinical trials. Check out these insights for more from our experts on Alzheimer's Disease or the use of AI to accelerate clinical trials:BLOG: Artificial Intelligence and Alzheimer's: Transforming Patient Screening with Predictive ModelsSyneos Health Podcast | Turbo-Charging Clinical TrialsWebinar | How AI is Supercharging Clinical TrialsArtificial Intelligence, Machine Learning and a New Epoch for Clinical TrialsThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Breast cancer is the most common type of cancer among women worldwide, and it can be treated with different modalities, such as surgery, chemotherapy, radiation, hormone therapy and targeted therapy. However, even after the primary treatment, some cancer cells may remain in the body and cause recurrence or metastasis. This is where adjuvant therapies come in: they are additional treatments that aim to reduce the risk of cancer coming back or spreading to other parts of the body.In this episode, Syneos Health colleagues Dr. Juan Manuel Carrera, Senior Medical Director and Lisamarie Burgio, Executive Director, Therapeutic Strategy and Innovation join the podcast to explore the role of adjuvant therapies in breast cancer, with a focus on the latest developments and challenges in this field. They share their extensive experiences and insights from both clinical and operational perspectives, emphasizing the importance of personalized treatment approaches based on the latest genomic information and the evolving landscape of clinical trials, offering a comprehensive view of the strides being made and the challenges that remain. For the latest oncology insights from our experts, check out: Bridging the Gap in Male Breast Cancer Research Through Inclusive Clinical Trial StrategyOncology and the Evolution of Master Clinical Trials | Lessons from the Beat AML Master TrialReadiness Assessment: What Strategies Can You Deploy to Improve Diversity in Your Oncology Trials?Syneos Health Podcast | The Case for Genetic MedicineIs Your NSCLC Asset Ready to Create Value Post-FDA Approval? | 2024 UpdateThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In March 2024, the FDA approved a groundbreaking gene therapy for children with a specific form of leukodystrophy, offering hope to those with no current care options. However, the approval came with a hefty price tag, making headlines as the most expensive medicine in the world at $3,500,000 per patient. With the cost of innovation so high, what can we do to de-risk development, ensure affordability and achieve equitable access to these potentially life-changing therapies for the long term?Nick Kenny, CSO for Syneos Health and host for this episode, is joined by colleagues Abhi Gupta, Head of Genetic Medicine, and Dr. Prateet Minhas, Managing Director, Value & Access Consulting, to explore the evolution of genetic medicines, from the early days of clinical trials fraught with challenges to the recent surge in approvals and the promise of curative potential. Abhi and Prateet discuss the landscape for genetic medicines today, touching on topics such as manufacturing challenges, regulatory considerations, and the importance of demonstrating durability of response in clinical development.As they navigate the complexities of the field, they address key questions surrounding the value proposition of genetic medicines, including their potential to transform patient outcomes and the challenges of reimbursement and access. They also examine the role of collaboration and innovation in driving progress in the field, highlighting the need for a balanced approach that prioritizes both scientific advancement and real-world impact. For more from our cell & gene therapy experts, check out these insights: BLOG: Three Lessons Learned in Adoptive Cell Therapy Trials: A Look at the Road Ahead for ImmunologyBLOG: A Holistic Approach to Genetic Medicines is Next for the Life Science IndustryExploring an Expedited Regulatory Pathway for Cell and Gene TherapiesBLOG: Cell and Gene Therapy Sponsors Must Overcome Unique Hurdles to Realize Promise to Patients The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Patient assistance programs can make a huge difference for patients who need expensive medicines but can't afford them. In this episode, Jeff Stewart talks with Dave MacLeod, Managing Director, Value & Access at Syneos Health about the benefits and challenges of patient assistance programs, which provide free or low-cost medicines to eligible patients. They discuss how these programs can improve access, adherence, and outcomes, as well as the operational and regulatory issues involved in running them. Covering key topics such as the Inflation Reduction Act (IRA), the impact of technology and AI in patient services, and the challenges posed by copay accumulators and maximizers, Dave sheds light on the complexities of navigating copay assistance optimization and the strategies employed to mitigate the effects on patients and manufacturers alike. For more from our Value & Access experts, check out these topics: Syneos Health Podcast | Real Talk About the Inflation Reduction ActBLOG: Industry Cheers “Co-Pay Accumulator” Ruling, Should Prep for What's Next Potential Impact of European Pharma Legislation on Commercialization and Access of New Therapies BLOG: What Can We Learn From ICER's New Value Framework Syneos Health Podcast | Market Access for Weight Loss Drugs MM+M Podcast | Gaining Access and Delivering Pull-Through in IDNs and Key Accounts  The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

The Inflation Reduction Act (IRA), signed into law by President Joe Biden in August 2022, brings significant changes to the U.S. pharmaceutical market as it rolls out over the next 10 years.Today we dive deep into the IRA with Tiffany McCaslin, Managing Director, Value, Access and Health Outcomes at Syneos Health. Drawing from her extensive background in healthcare policy and industry strategy, Tiffany offers invaluable insights into the practical implications of this landmark legislation for the pharmaceutical industry. From dissecting the intricacies of price negotiation to unraveling the complexities of data collection requirements, this episode provides a clear roadmap for pharmaceutical companies and life sciences firms navigating the post-IRA era. For more from our Value & Access experts, check out these insights: BLOG: Industry Cheers “Co-Pay Accumulator” Ruling, Should Prep for What's Next Potential Impact of European Pharma Legislation on Commercialization and Access of New Therapies BLOG: What Can We Learn From ICER's New Value Framework Syneos Health Podcast | Market Access for Weight Loss Drugs MM+M Podcast | Gaining Access and Delivering Pull-Through in IDNs and Key Accounts BLOG: What ICER's Draft Sickle Cell Disease Report Means for CGT Pricing The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

For the first time, the technology behind Wall Street and Formula One racing is being used in pharmaceuticals—and it's offering unparalleled potential for innovation in clinical trial execution and healthcare delivery.In this episode, host Jeff Stewart is joined by Darren Coleman, the general manager of RxDataScience, a Syneos Health company, who discusses KX technology, the world's fastest time series database and analytics engine, and how it is now being applied to improve clinical trial efficiency, reduce costs and speed time to market for life-changing therapies for patients. From current applications to optimize site selection, predict enrollment rates, and identify trial risks months in advance, to future use cases including patient selection and predicting drug efficacy, Coleman outlines exciting possibilities for the future of clinical trials and healthcare.For more from Syneos Health on AI applications in biopharma, check out these insights:WEBINAR | How AI is Supercharging Clinical TrialsSyneos Health Podcast | 2024 Health Trends: Managing the Healthcare RevolutionIt's Time We Got the Most Out of Medical Affairs DataArtificial Intelligence, Machine Learning and a New Epoch for Clinical Trials The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

When it comes to launching a pharmaceutical product in today's market—especially as an emerging company—strategic investment can make all the difference.Drawing from a recent study on investing for commercial success, Michael Sarshad, Managing Director in the Commercial Advisory Group at Syneos Health, discusses the key factors for successfully launching a drug in today's market; the importance of strategic investment, timing and team experience in exceeding launch forecasts; and the diverse areas where this investment is crucial, from medical affairs and market access to clinical strategy and supply chain logistics.Tune in for expert insights into the intricacies of launching pharmaceutical products and how strategic investment can make all the difference.For more of our insights on launch and commercialization, check out this content on our Insights Hub: Investing for Launch Success: The “Goldilocks” RatioInvesting for Launch Success: Tailoring Your Strategy for EuropeGood Science Is Not Good Enough: For Emerging Companies, Differentiation Requires a Commercial Value Creation StorySupporting the Launch of BiosimilarsWEBINAR | The Three Perils of Cross-Functional Commercialization: Time, Insight and IntegrationThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Age-related vision loss is a rising concern for our growing aging population. According to the most recent data published by the CDC, nearly 20 million Americans aged 40+ have been diagnosed with some form of age-related macular degeneration (AMD). By the age of 75, roughly 1 in 3 people living in the United States will have some form of AMD, and about 1 in 4 of those will have a vision-threatening, late-stage form of AMD. These statistics underscore the need for heightened public awareness and increased accessibility to innovative treatments.February is Low Vision and Age-Related Macular Degeneration (AMD) Awareness Month. In this episode, Laszlo Bekesi, MD, Vice President of Strategy and Innovation, and Jonathan Angelastro, Executive Director of Project Delivery at Syneos Health provide valuable insights into the evolving field of ophthalmology and the efforts to address the growing burden of age-related vision impairment—with a  focus on understanding both wet and dry AMD types, the complexities of AMD, its impact on vision and the urgency for early detection and treatment. They also discuss the current landscape of research and development in the space and highlight the opportunities for—and inherent operational challenges of—conducting clinical trials in ophthalmology.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Dominic (Nick) Marasco, Executive President and Chief Commercial Officer at Envision Pharma Group. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Nick, covering: Building businesses, learning lots, and selling BioAgilytix With many options on the table... what was it that attracted him to Envision Pharma Group The real-life benefits and tangible impact of AI for pharma and biopharma companies Why great science and outstanding services that help will continuously be funded, irrespective of the ebbs and flows of the market Dominic (Nick) Marasco is an entrepreneurial executive. He has over 25 years of executive experience in C-suite strategic planning, commercial operations, global business development, clinical Phase III trial design strategy, alliance management, financial resourcing, and P&L oversight within the Pharmaceutical, Biotech, and Medical Device industries. Before joining Envision Pharma Group as Executive President and Chief Commercial Officer, Dominic served as Chief Commercial Officer of BioAgilytix, and in his tenure, he was actively involved in two buyer-side acquisitions and three integrations, as well as a seller-side sale of the company to new private equity owners, all within a 24-month timeframe. Before BioAgilytix, he served as Executive Vice President of Global Business Development and Commercial at Syneos Health, where he led the overall strategic direction of the worldwide business development team for the commercial division both in the U.S. and internationally. He was previously Head of U.S. Sales for the Neuroscience Business Unit at Amgen, Inc., and before that, Global Commercial Head of Amgen Biosimilars. Dominic has also held commercial positions at Sandoz Biopharmaceuticals (a Novartis company). He received his Bachelor of Science in Pharmacy from the Philadelphia College of Pharmacy and Science and ais an alum of the Harvard Business School Advanced Management Program. Dominic resides in Nevada. Connect on LinkedIn: here ---- Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.  

The FDA has finalized a rule that addresses how drug ads must be presented in TV and radio commercials. The rule, proposed in 2010 and now effective from May of this year, aims to provide clarity and guidelines for pharmaceutical companies in presenting side effects and contraindications in a balanced manner. But it's still a 27-page document.Here, we'll boil it down for you.Matthew Snodgrass, head of US Digital and Social Strategy at Syneos Health, sheds light on the 13-year journey from proposal to finalization, exploring key aspects of the rule, restrictions on distracting visuals during side effect discussions, and the use of quantitative terminology to convey information more precisely. The conversation delves into the challenges faced by regulatory teams in interpreting and implementing these rules and highlights the importance of understanding and following FDA guidelines in pharmaceutical advertising.For a more detailed exploration of the FDA rule, check out our highlighted version of the full document in a downloadable PDF format. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Recorded at NC Life Sciences Organization's Annual Meeting, our hosts Heather and Matthew welcome Shirley Paddock, Senior Vice President of Clinical Development for Syneos Health. She shares exciting insights on the acceleration of clinical and commercial pharmaceutical solutions and how Syneos is designed to help clients' clinical development and research needs. Listen to episode 169 now!

This episode is sponsored by Syneos Health®, a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. Syneos translates unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. Together they share insights, use the latest technologies and apply advanced business practices to speed customer delivery of important therapies to patients. Syneos supports a diverse, equitable and inclusive culture. To learn more about how Syneos is shortening the distance from lab to life®, visit syneoshealth.com. Mark Freebery, MSL Regional Director East, and Rachel Pater, Community Medical Liaison Director, West at Syneos Health discuss the importance of investing in people and putting interpersonal relationships first, business second. Mark and Rachel share…

October is National Depression and Mental Health Screening Month, with October 10th specifically recognized as World Mental Health Day. A recent study co-led by Harvard Medical School and the University of Queensland established that one out of every two people in the world will develop a mental health disorder in their lifetime. This staggering number underscores the critical need to reduce the stigma of mental health, and to make sure that people who are suffering understand the diverse help and treatment options that are available to them.Dr. Alexandria Wise, Global Head of Therapeutic Strategy and Innovation and Andy Moniz, VP, Therapeutic Strategy and Innovation at Syneos Health, join the podcast to help raise mental health awareness, discussing the evolution in mental health treatment over the past 30 years and where it stands today; the challenges of mental healthcare access for certain patient groups and what is being done to ease this; and the unique aspects of psychedelics in mental health clinical trials and their potential for promising results.For more content on neuroscience topics, check out these insights:Understanding the Role of the Placebo Response in Clinical TrialsDigital Flexibility and the Digital Divide: Meeting Patients Where They're At With Mental Health ServicesWEBINAR | Psychedelics 3.0: Drug Development Challenges and Opportunities in a Rapidly Evolving FieldThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Radiosensitizers have emerged as potential game-changers in head and neck cancer therapy. A diverse group of compounds, radiosensitizers enhance radiation therapy's impact on tumor cells. Ongoing research seeks radiosensitizers that augment radiotherapy's efficacy without increasing toxicity, offering exciting prospects for the APAC region and beyond.Our new APAC Edition host Lance Eminger, Executive Director of Business Development is joined by Dr. Juan Manuel Carrera, Senior Medical Director at Syneos Health to discuss what radiosensitizers are and how they work—highlighting the potential of new radiosensitizers to redefine cancer treatment, fostering better results with fewer side effects.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

One of the biggest trends making headlines and impacting the healthcare industry to date is the rising popularity of GLP-1 drugs. Initially developed for diabetes management, these products have recently gained traction for weight loss indications. But with promising efficacy and growing popularity, is the healthcare industry truly prepared for the challenges posed by these drugs becoming such a hot commodity in the market?Tom Albers, Vice President of Strategy at Syneos Health company Spherico, joins the podcast to discuss his insights on the future of weight loss drugs – payer challenges, the transformative potential of these drugs, and the need for smart investments in data and evidence.For more content on value and access, check out these insights: MM+M Podcast | Gaining Access and Delivering Pull-Through in IDNs and Key AccountsSyneos Health Podcast: The Inflation Reduction ActBuilding a Market Access Case for Real World Evidence in OncologyThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

In this episode of the Syneos Health Podcast, we embark on a journey into the metaverse – a revolutionary concept that's transforming the way we approach training and learning. As we delve into the world of the metaverse and its implications for healthcare training, Michael Shim, PharmD, National Director, Field Medical Affairs and Marie Latsa, PharmD, Community Medical Director at Syneos Health, will share their firsthand experiences with metaverse-based training for Medical Science Liaisons (MSLs), and provide valuable insights into the current state and future potential of this cutting-edge technology that offers an immersive and efficient training alternative.Join us on this exciting journey into the metaverse and discover its role in shaping the future of education and training in healthcare.For more of our insights on MSLs and Medical Affairs, check out these pieces on our Insights Hub:A Field MSL Perspective on Tech-Enablement Using the MetaverseLeveraging Metaverse Capabilities for Medical AffairsMedical Science Liaisons: Your Role in Creating a Culture of ExcellenceEarly Adoption of Metaverse Technology in Medical AffairsUsing Omnichannel to Drive Integration between Medical and CommercialEngaging Patient Communities: The Changing Role of Medical AffairsThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Just taking a moment here to thank our Relentless Tribe for really getting yourselves involved in the work that I had originally kicked off to improve the outcomes for CKD (chronic kidney disease) patients in this country. With the momentum that we have so far, this Relentless Tribe of ours, we are really (for reals) going to produce measurable improvements for patients with CKD—so many of you, not just talking but actually out there, actively doing what you need to do so that patients do better, and it's making a difference. I have talked to doctors, other clinicians, administrators, IPAs, other provider organizations big and small, payers, societies, a great data company, a number of you who are consultants. It's crazy what we have been able to build so far, and we've been doing this for less than a year. The Relentless Tribe … let me tell you, we move mountains. We get patients properly diagnosed. We get them into appropriate treatment plans. What restores my faith in these rough times, we have encountered one PCP, one clinician after another; and the second that we show them the “as per the guidelines” way to accurately diagnose and stage chronic kidney disease (which is not just using eGFR for those clinicians who might be listening), yeah, that's it! These are great doctors, and they switch it up. They switch up what they are doing, and that makes my heart warm. These are doctors across the board, from ones in independent practices to ones maybe employed by academic medical centers. And once they have the right information, they use it. And it's a wonderful thing, and I cannot thank everybody who has contributed enough. We are making real differences in patients' lives. If what I am doing speaks to you in any way, please hit me up, because we're cooking with gas and I could not be prouder of this community of change agents that we have built here. You're amazing. You know what needs to be done, and you're not afraid to do it. Now, back to our regularly scheduled programming. In this healthcare podcast, I am talking with Secretary David Shulkin, MD, and Erin Mistry. Here's the first reason why I was interested in taking this interview after their public relations firm contacted me. We were at the thINc360 conference in DC earlier this summer, and I heard them talking about a new innovation to help patients on dialysis not die from infections, which … didn't realize how common that was and it seemed like a nice adjacency to our ongoing CKD work. I also thought this might be an opportunity to learn a little bit more about what's going on with hospital-acquired infections and infection control. Superbugs are hella scary, but one thing I'm just gonna point out—and, small sidebar here, but listen to the show with Bruce Rector, MD (EP300) for more on this—in recent times, I don't think there has been a pharma company who has managed to launch an antibiotic and achieve commercial success. So, what can easily wind up happening under the current payment model is that instead of just using the new antibiotic to treat resistant cases, there's this perverse incentive to push for the drug's use more broadly because more prescriptions, more money. But when the new antibiotic is used more broadly, that actually reduces its effectiveness against those resistant infections that it is here to treat. Okay … back to bloodstream infections now, which is the topic of the conversation today. If a patient has a central line infection and then gets sepsis, their chances of readmission within 30 days is almost 99%. This is not a little cohort. It's not small potatoes we're talking about here either. As Secretary Shulkin says during this interview that follows, if you're gonna make a preventative care economic case study, do it on hospital-acquired infections and, most particularly, those with central lines that lead to sepsis. Even with very short time horizons, you can make that case. So, that was two reasons for this interview. The third: I've been extremely intrigued by how and why decisions get made in hospitals for whether or not to buy and use potentially expensive new innovative things—specifically, innovative new things which are used during inpatient goings-on paid for with a DRG. DRG stands for Diagnostic Resource Group. Medicare (and others a lot of times) pays hospitals a flat sum to care for a patient coming in with heart failure or sepsis or needing dialysis, regardless of what services are actually delivered. There are something like 13,000 diagnoses and 5000 procedures that Medicare pays for with a DRG lump sum payment. It's up to the hospitals to make sure they buy low and sell high. So, you can see where this is going. A hospital can't go tell Medicare, “Hey, we just got some fancy new equipment or a better IV drug, so now we're gonna charge more.” The DRG is what the DRG is, and if the hospital chooses to spend more on the cost of goods, then the hospital makes less money. This is kind of along the same lines as Marty Makary, MD, MPH, talks about in his book Unaccountable. The purchasing department or some administrator somewhere is making decisions about what monitors to put in the ORs, and they pick the cheap ones that don't have the color contrast that the surgeons need to do a good job. But the monitors are cheaper, and the hospital can't pass on the costs. So, from a strictly purchasing perspective, it seems like fiscally solid purchasing, even if doctors are not on board with the decisions and patients have worse outcomes. Seems like somebody over at CMS figured this out, and to solve for the “purchasers or administrators or whomever who are not willing to lose money by using new stuff,” Medicare introduced this extra payment opportunity, which we'll get into in the interview today. But the short version is this: Biotech companies, device companies, others who are innovators can apply to get Medicare to pay a so-called NTAP to healthcare delivery organizations who use the new product. NTAP stands for new technology add-on payment. Again, these are additional Medicare payments in the inpatient setting that may be available to those who use certain qualifying new technologies as part of services rendered that are normally part of a DRG. Here's my assessment of the tension between hospitals and plan sponsors because, yeah, when hospitals get paid more for something, that is coming out of somebody's wallet. If we assume that we're talking about an innovation that actually produces better patient outcomes, I don't know how anyone can say there's a right answer here. If the innovation is expensive, you're gonna have payers worried about the money, and fair enough. I can easily hear them saying something like, “We're already paying however much to the hospital, and now there's an additional charge that's allowed on top of the DRG?” On the other hand, if I'm a patient, yeah, it would kinda suck to not get the innovation that's gonna save my life or whatever because the payers insist on paying no more than the DRG and the hospital won't pay out of their own pocket. Really enjoyed my conversation today with Secretary David Schulkin. Secretary Shulkin spent his career running healthcare systems, mostly in the Northeast. A number of years ago, he entered the Obama administration to run the VA (Veterans Affairs) healthcare system. In the Trump administration, Dr. Shulkin was in the Cabinet as the Secretary of the Department of Veterans Affairs. Secretary Shulkin now has a consulting firm and is working with CorMedix. Erin Mistry, my second guest today, spent her career in health systems and then in biopharma. She now works for CorMedix. My sincere thanks for helping validate a couple of facts in this intro to Scott Haas, Autumn Yongchu, and Erik Davis from USI. For more on the topic of hospitals getting paid to administer drugs through a patient's medical benefit, listen to the show with Autumn Yongchu and Erik Davis (EP370). They cover the ways hospitals sometimes can figure out how to charge plan sponsors and patients 6x the cost of the drug. Acronym alert! CVC, which comes up a couple of times in the interview that follows, stands for central venous catheter, which is something that many dialysis patients have. Second Acronym Alert! QIDP stands for Qualified Infectious Disease Product. A QIDP qualifies for a special NTAP incentive specifically for infectious disease products. So again, just recapping what an NTAP is. It's a new technology add-on payment, and it's paid for by CMS, who has studied the new technology thing and determined that they actually want hospitals to be using it. So, they're willing to pay more than the DRG if a hospital uses this thing, because they recognize if they don't pay more, then the hospital won't eat the cost. And just because of all the focus on infectious disease right now, these qualified infectious disease products have some prioritized status over at CMS relative to getting the NTAP designation.   You can learn more by connecting with Secretary Shulkin, Erin, and CorMedix on LinkedIn.     Honorable David J. Shulkin, MD, was the ninth Secretary of the US Department of Veterans Affairs (VA), having been appointed by President Trump. Secretary Shulkin previously served as Under Secretary for Health, having been appointed by President Obama and confirmed twice unanimously by the US Senate. As Secretary, Dr. Shulkin represented the 21 million American veterans and was responsible for the nation's largest integrated healthcare system, with over 1200 sites of care serving over 9 million veterans. Prior to coming to VA, Secretary Shulkin was a widely respected healthcare executive, having served as chief executive of leading hospitals and health systems, including Beth Israel in New York City and Morristown Medical Center in northern New Jersey. As an entrepreneur, Secretary Shulkin founded and served as the chairman and CEO of DoctorQuality and has served on boards of managed care companies, technology companies, and healthcare organizations. Since leaving government, Secretary Shulkin has been the University of Pennsylvania Leonard Davis Institute Distinguished Health Policy Fellow and Professor at the Jefferson University College of Population Health. He is a board-certified internist and received advanced training in outcomes research and economics as a Robert Wood Johnson Foundation Clinical Scholar at the University of Pennsylvania. Over his career, Secretary Shulkin has been named one of the “100 Most Influential People in American Healthcare” by Modern Healthcare.   Erin Mistry is executive vice president and chief commercial officer of CorMedix, appointed in January 2023. She served as senior vice president of payer strategy, government affairs, and trade from 2020 to 2022. She leads the company's commercial strategy and execution. Erin brings over 15 years of industry experience at the executive level, from consulting to in-house executive management. Prior to joining CorMedix, Erin was vice president of market access at Intarcia Therapeutics, responsible for pricing, coverage, access, real-world evidence (RWE), and channel strategy for a competitive product in type 2 diabetes. Erin was also senior managing director at Syneos Health, where she was responsible for the global P&L of the Value Access Practice. In this capacity, Erin consulted on commercial strategy and market access with emerging, mid, and large biopharma across a broad range of therapeutic categories. Erin holds an undergraduate and master degree in biomechanical engineering from North Carolina State University.   10:17 What is happening with antimicrobial stewardship and combatting antibiotic resistance? 11:22 How is CorMedix working to prevent infections caused by catheters, and who is paying for the innovation to prevent this type of infection? 12:38 Why should hospitals pay for new innovations like the one created by CorMedix? 14:32 What do hospitals need to do in order to realize the benefit of this new innovation? 16:14 What does antimicrobial stewardship mean to Secretary Shulkin? 17:06 “If we continue to ignore this and not use antibiotics appropriately, it's simply a matter of time before the superbugs figure out how to take over.” —Secretary Shulkin 18:32 “Anytime you have a preventative medicine, you have to have an economic story.” —Erin 20:55 Who is using this product, and who is paying for it? 21:38 What needs to be considered if rolling out an innovation like this broadly? 24:47 How does an innovative product qualify for an NTAP? 26:37 “It's not just financial economics; it's mortality data.” —Erin 28:08 What does Secretary Shulkin see as “shifting the paradigm”?   You can learn more by connecting with Secretary Shulkin, Erin, and CorMedix on LinkedIn.   @DavidShulkin and Erin Mistry of @CorMedix_News discuss payment for #innovation in #hospital procedures and #DRG on our #healthcarepodcast. #healthcare #podcast #digitalhealth #hcmkg #healthcarepricing #pricetransparency #healthcarefinance   Recent past interviews: Click a guest's name for their latest RHV episode! Keith Passwater and JR Clark (Summer Shorts 7), Lauren Vela (Summer Shorts 6), Dr Jacob Asher (Summer Shorts 5), Eric Gallagher (Summer Shorts 4), Dan Serrano, Larry Bauer, Dr Vivek Garg (Summer Shorts 3), Dr Scott Conard (Summer Shorts 2), Brennan Bilberry (Summer Shorts 1), Stacey Richter (INBW38)

It's been a hot and heavy summer, and the pipeline is looking encouragingly full for next month — especially compared to this time last year.For this week's episode of the podcast, Will Caiger-Smith and William Hoffman take a tour through the primary calendar and evaluate each deal's chances for a smooth syndication.Featuring: Worldpay, Vistra, Syneos Health, Simon & Schuster…and many more. Check out our piece from earlier this week for the full slate.

The emergency department (ER) can be a place of chaos, panic and infinite amounts of unpredictability. Not knowing what can come through the doors at any given time makes this environment impossible to foresee and prepare for.  Because of this uncertainty, the ER (and its patients) can be a particularly challenging target for clinical trials.  In this episode, Dr. Ruth Henrice-Desrosiers, Medical Director, Syneos Health joins the podcast to discuss critical aspects to be considered by biopharma companies when choosing to bring a clinical trial to the ER—from location and cost implications to informed consent challenges, and everything in between.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

The game continues to change in biotech as continued macroeconomic uncertainty has far reaching implications for the future of the biopharma ecosystem. Biotechs can no longer operate toward the single goal of being acquired by, or of licensing their assets to, large pharma—and players may need to develop products further than in the past, and therefore strategic pathway optionality needs to be weaved into and maintained throughout product and corporate development. But with a multitude of new challenges facing this industry come multifold new opportunities for value creation and chances to reach new heights. In this episode, Lee Taurman, Global Head of Syneos One and Keith Ruark, SVP Strategic Business Development, Syneos Health are joined by Ali Pashazadeh and Max Baumann, Co-Founders of Treehill Partners, to discuss strategic and operational implications for the biotech C-suite and share perspectives on how companies can succeed in an increasingly competitive environment.  learn strategic and operational implications for the biotech C-suite and share perspectives on how companies can succeed in an increasingly competitive environment. The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

What is the healthcare industry up against in terms of recruiting, hiring, and retention, in the increasingly competitive job markets of China, Korea and Japan? Leigh Householder and Sam Wilson, commercial solutions lead for APAC, Syneos Health,  discuss how changing customer needs, evolving market dynamics and shifts in customer engagement  continue to be  challenges when recruiting top talent in the region.Learn more about 2023 Health Trends here.More Episodes in the 2023 Health Trends Series:Syneos Health Podcast: 2023 Health Trends: Personally, Purposefully Building What's NextTrend Talks: AgeTech with Musician, Actor & Patient Advocate, James IanTrend Talks: AI: Finally fit for PurposeTrend Talks: A New Field for the Field Force Trend Talks: The Data EffectThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

Digital therapeutics (DTx) are projected to be $50 billion industry by 2025. While many minds may immediately jump to unregulated companion apps when they hear “digital,” there are also clinically validated prescription digital products that act complementary to or in combination with traditional biopharmaceutical therapies. As these prescription DTx gain traction, how can companies harness their power to improve their brand's value proposition? In this first of two episodes on DTx, Michael Sarshad, Managing Director, Commercial Advisory at Syneos Health and Austin Speier, Chief Strategy Officer, Click Therapeutics, join the podcast to discuss the growing market and opportunities for DTx across the product lifecycle, where DTx can add value and ways to think about how to integrate them into a brand strategy. For a deeper dive into how companies can implement DTx to expand or augment the potential of their pharmaceutical and biologic therapeutic assets, read our article 10 Ways to Optimize and Accelerate Brand Performance using Prescription DTx.The views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.

"It's July 2022. This morning I tried to donate my kidney, this afternoon the transplant team told me that I can't, I have cancer." Words no one wants to hear. Even for a former Jeopardy! champion with degrees in molecular biology and two decades of experience in the biopharma industry, the implications of the phrase are overwhelming.Nearly a year later, our flagship podcast host Jeff Stewart is telling his story.Today, Nick Kenny, Chief Scientific Officer at Syneos Health, turns the tables on Jeff, interviewing him on his recent experience being diagnosed and undergoing treatment for two separate cancers. They discuss the realities today for patients like Jeff who are dealing with complex cancer diagnoses—including information overload both fake and real, and the importance of “pre-bunking”—and his newly released book, Living: Inspiration from a Father with Cancer.At a time when regulators in our industry at large are increasingly and rightly focused on patient perspectives in drug development, and with ASCO, the single largest global gathering of about 50,000 clinical cancer experts right around the corner in early June, this is a very timely discussion.Read excerpts of the book on NPR.Check out our other content on the patient experience:Webinar: Patient Perspectives as Essential in Next-Generation Clinical TrialsExploring the Value and Impact of Patient-Reported Outcomes in Patient-Centric CAR-T Clinical Trials3 Ways Patient Voice is Impacting Rare Disease Research, According to AdvocatesThe views expressed in this podcast belong solely to the speakers and do not represent those of their organization. If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you'll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision-making and investment. You can find it all at insightshub.health. Like what you're hearing? Be sure to rate and review us! We want to hear from you! If there's a topic you'd like us to cover on a future episode, contact us at podcast@syneoshealth.com.